Bicara Therapeutics (BCAX) Share-based Compensation (2023 - 2026)
Bicara Therapeutics posted quarterly Share-based Compensation of $5.9 million for Q1 2026, up 69.75% year-on-year from $3.5 million in Q1 2025, and up 31.67% on a QoQ basis from $4.4 million in Q4 2025.
Bicara Therapeutics (BCAX) has 4 years of Share-based Compensation data on file, last reported at $5.9 million in Q1 2026.
- For the quarter ending Q1 2026, Share-based Compensation rose 69.75% year-over-year to $5.9 million; the trailing twelve-month figure through Mar 2026 stood at $17.4 million (up 79.5% YoY), and the FY2025 full-year result was $15.0 million, up 102.87% from the prior year.
- Share-based Compensation for Q1 2026 stood at $5.9 million, up from $4.4 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $5.9 million in Q1 2026 and bottomed at $765000.0 in Q4 2023.
- The 4-year median for Share-based Compensation is $3.3 million (2024), against an average of $2.9 million.
- The widest annual swing landed in 2024, when Share-based Compensation jumped 315.82%; it then soared 39.86% in 2025.
- A 4-year view of Share-based Compensation shows it stood at $765000.0 in 2023, then surged by 315.82% to $3.2 million in 2024, then jumped by 39.86% to $4.4 million in 2025, then surged by 31.67% to $5.9 million in 2026.
- The last three Share-based Compensation figures came in at $5.9 million (Q1 2026), $4.4 million (Q4 2025), and $3.6 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 892,057.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 305,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 166.40 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 257.40 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 70.15 Mn |
| 10 | Bicara Therapeutics | 1.25 Bn | 1.25 Bn | - | 5.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.86 Mn |
| Mar 31, 2026 | 5.86 Mn |
| Dec 31, 2025 | 4.45 Mn |
| Dec 31, 2025 | 4.45 Mn |
| Sep 30, 2025 | 3.61 Mn |
| Sep 30, 2025 | 3.61 Mn |
| Jun 30, 2025 | 3.49 Mn |
| Jun 30, 2025 | 3.49 Mn |
| Mar 31, 2025 | 3.45 Mn |
| Mar 31, 2025 | 3.45 Mn |
| Dec 31, 2024 | 3.18 Mn |
| Dec 31, 2024 | 3.18 Mn |
| Sep 30, 2024 | 2.03 Mn |
| Sep 30, 2024 | 2.03 Mn |
| Jun 30, 2024 | 1.04 Mn |
| Jun 30, 2024 | 1.04 Mn |
| Mar 31, 2024 | 1.15 Mn |
| Mar 31, 2024 | 1.15 Mn |
| Dec 31, 2023 | 765,000.00 |
| Dec 31, 2023 | 765,000.00 |